SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden	
hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*
Cavorsi Robert

(Last) (First) (Middle)

C/O ORGANOGENESIS HOLDINGS INC.
85 DAN ROAD

(Street)

CANTON MA 02021

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
04/19/2024

3. Issuer Name **and** Ticker or Trading Symbol
Organogenesis Holdings Inc. [ORGO]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)

Vice President, Strategy

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Class A Common Stock	23,579(2)	D	
Class A Common Stock(1)	739(3)	D	
Class A Common Stock(1)	215(3)	D	
Class A Common Stock(1)	2,163(4)	D	
Class A Common Stock(1)	4,203(5)	D	
Class A Common Stock(1)	51,750(6)	D	
Class A Common Stock(1)	57,434(7)	D	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Option (Right to Buy)	(8)	03/09/2031	Class A Common Stock	6,519	$15.63	D	
Stock Option (Right to Buy)	(9)	07/16/2031	Class A Common Stock	32,559	$14.45	D	
Stock Option (Right to Buy)	(10)	03/01/2032	Class A Common Stock	19,935	$8.03	D	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)							
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Option (Right to Buy)	(11)	03/15/2033	Class A Common Stock	81,000	$2.51	D	
Stock Option (Right to Buy)	(12)	02/21/2034	Class A Common Stock	103,842	$3.43	D	

Explanation of Responses:

1. Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock.
2. Represents shares of Class A Common Stock of Organogenesis pursuant to vested RSUs under the 2018 Equity Incentive Plan.
3. The RSUs vest in equal annual installments over four years beginning March 9, 2021, and shall become fully vested on March 9, 2025.
4. The RSUs vest in equal annual installments over four years beginning July 16, 2021, and shall become fully vested on July 16, 2025.
5. The RSUs vest in equal annual installments over four years beginning March 1, 2022, and shall become fully vested on March 1, 2026.
6. The RSUs vest in equal annual installments over four years beginning February 15, 2023, and shall become fully vested on February 15, 2027.
7. The RSUs vest in equal annual installments over four years beginning February 15, 2024, and shall become fully vested on February 15, 2028.
8. The option becomes exercisable in equal annual installments over four years beginning March 9, 2021, and shall become fully vested and exercisable on March 9, 2025.
9. The option becomes exercisable in equal annual installments over four years beginning July 16, 2021, and shall become fully vested and exercisable on July 16, 2025.
10. The option becomes exercisable in equal annual installments over four years beginning March 1, 2022, and shall become fully vested and exercisable on March 1, 2026.
11. The option becomes exercisable in equal annual installments over four years beginning February 15, 2023, and shall become fully vested and exercisable on February 15, 2027.
12. The option becomes exercisable in equal annual installments over four years beginning February 15, 2024, and shall become fully vested and exercisable on February 15, 2028.

Remarks:

Exhibit 24 Power of Attorney filed herewith.

/s/ William R. Kolb, Attorney-in-Fact	04/29/2024
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, *see* Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.